1698293-93-4

Usage

Uses

Used in Pharmaceutical Industry:
4-methyl-2-(1-methylethyl)-3-pyridinamine is used as a reagent for the preparation of KRAS G12C inhibitors, which are crucial in the treatment of pancreatic, colorectal, and lung cancers. These inhibitors target the KRAS protein, a common mutation found in various types of cancer, and help in suppressing tumor growth and progression.

Upstream product

• 65169-38-2 2-chloro-4-methyl-3-pyridinecarbonitrile 
• 65996-02-3 2-bromo-4-methylpyridine-3-carbonitrile 
• 93271-59-1 1,2-dihydro-2-oxo-4-methylpyridine-3-carbonitrile 
• 920-39-8 isopropylmagnesium bromide 
• 126325-50-6 3-amino-2-bromo-4-methylpyridine 
• 29509-06-6 4-methyl-3-oxopentanonitrile 
• 133627-45-9 3-Amino-2-chloro-4-methylpyridine 
• 1269438-44-9 4-methyl-3-nitro-2-isopropenylpyridine 
• 23056-39-5 2-chloro-3-nitro-4-methylpyridine 
• 1068-55-9 isopropylmagnesium chloride 
• 77047-87-1 isopropyl zinc bromide 

Downstream Products

• 2252403-82-8 7-chloro-6-fluoro- 1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 2252403-56-6 (1R)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1H)-one 
• 2252403-82-8 7-chloro-6-fluoro-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 2252403-82-8 (P)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 

Relevant academic research and scientific papers

Synthesis method of 2-isopropyl-3-amino-4-methylpyridine

The invention discloses a preparation method of 2-isopropyl-3-amino-4-methylpyridine, and the preparation method comprises the following specific steps: (1) carrying out a reaction on 3-cyano-4-methyl-2-pyridone and phosphorus oxybromide to obtain 2-bromo-3-cyano-4-methylpyridine, (2) hydrolyzing the 2-bromo-3-cyano-4-methylpyridine by using concentrated sulfuric acid, so as to obtain 2-bromo-4-methyl nicotinamide; (3) reacting the 2-bromine-4-methyl nicotinamide with a sodium hypochlorite solution under the condition of sodium hydroxide, and carrying out Hofmann rearrangement to obtain 2-bromine-3-amino-4-methylpyridine; and (4) enabling the 2-bromo-3-amino-4-methylpyridine to react with an isopropyl Grignard reagent under the action of a catalyst containing iron or nickel, so as to obtain the 2-isopropyl-3-amino-4-methylpyridine. The method disclosed by the invention is low in cost and simple to operate, and is a novel method for synthesizing the 2-isopropyl-3-amino-4-methylpyridine.

Preparation method of Sotorasib intermediate

The invention discloses a preparation method of a Sotorasib intermediate 2-isopropyl-3-amino-4-methylpyridine. The preparation method comprises the following specific steps of: (1) carrying out a reaction on 3-cyano-4-methyl-2-pyridone and a halogenating reagent to obtain 2-halogenated-3-cyano-4-methylpyridine; (2) making the 2-halogenated-3-cyano-4-methylpyridine with an isopropyl Grignard reagent under the action of a catalyst, so as to obtain 2-isopropyl-3-cyano-4-methylpyridine; (3) carrying out hydrolysis on the 2-isopropyl-3-cyano-4-methylpyridine, so as to obtain 2-isopropyl-4-methyl nicotinamide; and (4) carrying out Hofmann rearrangement on the 2-isopropyl-4-methyl nicotinamide, sodium hydroxide and a sodium hypochlorite solution, so as to obtain the 2-isopropyl-3-amino-4-methylpyridine. The preparation method disclosed by the invention is low in cost and simple to operate, and is a novel method for synthesizing the 2-isopropyl-3-amino-4-methylpyridine.

IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND

The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to inhibitors of one or more isoforms of RAS, such as inhibitors of one or more of KRAS, HRAS and NRAS, or mutants thereof, such as G12D, G12V, G13D or G12C mutants thereof. Therapeutic methods of treating conditions and diseases using these inhibitors are also provided.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to inhibitors of one or more isoforms of RAS, such as inhibitors of one or more of KRAS, HRAS and NRAS, or mutants thereof, such as G12D, G12V, G13D or G12C mutants thereof. Therapeutic methods of treating conditions and diseases using these inhibitors are also provided.

Synthesis method of 2-isopropyl-3-amino-4-methylpyridine

The invention discloses a synthesis method of 2-isopropyl-3-amino-4-methylpyridine, wherein the synthesis method comprises the steps: by taking ethyl isobutyrate as a raw material, sequentially carrying out condensation, aldol condensation, methylation condensation and aminopyridine cyclization to obtain AMG-2, and then carrying out hydrolysis and Hofmann degradation to obtain the 2-isopropyl-3-amino-4-methylpyridine. The method has the advantages of cheap and easily available raw materials, mild conditions, simple and safe operation, high reaction selectivity, high product yield and purity, low cost and wide application prospect.

Kras-G12C inhibitor heterocyclic compounds

The invention relates to Kras-G12C inhibitor heterocyclic compounds and a preparation method thereof, and application of the compounds in prevention and treatment of tumor diseases such as lung cancer, colorectal cancer and pancreatic cancer. In the preparation process, the compounds provided by the invention are obtained through a series of reactions such as a condensation reaction, an intramolecular cyclization reaction, a chlorination reaction, an SN2 reaction, a coupling reaction, deprotection and the like.

KRAS MUTANT PROTEIN INHIBITOR

Provided herein are a KRAS mutant protein inhibitor, as shown by formula (I), a composition containing the inhibitor and the use thereof.

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and

KRAS MUTANT PROTEIN INHIBITORS

The invention relates to a KRAS mutant protein inhibitor shown as formula (I), a composition containing the inhibitor and the use thereof.